Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial.
Wagemann O, Liu H, Wang G, Shi X, Bittner T, Scelsi MA, Farlow MR, Clifford DB, Supnet-Bell C, Santacruz AM, Aschenbrenner AJ, Hassenstab JJ, Benzinger TLS, Gordon BA, Coalier KA, Cruchaga C, Ibanez L, Perrin RJ, Xiong C, Li Y, Morris JC, Lah JJ, Berman SB, Roberson ED, van Dyck CH, Galasko D, Gauthier S, Hsiung GR, Brooks WS, Pariente J, Mummery CJ, Day GS, Ringman JM, Mendez PC, St George-Hyslop P, Fox NC, Suzuki K, Okhravi HR, Chhatwal J, Levin J, Jucker M, Sims JR, Holdridge KC, Proctor NK, Yaari R, Andersen SW, Mancini M, Llibre-Guerra J, Bateman RJ, McDade E; Dominantly Inherited Alzheimer Network–Trials Unit. Wagemann O, et al. Among authors: scelsi ma. JAMA Neurol. 2024 Apr 29:e240991. doi: 10.1001/jamaneurol.2024.0991. Online ahead of print. JAMA Neurol. 2024. PMID: 38683602 Free PMC article.
At-Home Administration of Gantenerumab by Care Partners to People with Early Alzheimer's Disease: Feasibility, Safety and Pharmacodynamic Impact.
Boess FG, Scelsi MA, Grimmer T, Perry RJ, Tonietto M, Klein G, Hofmann C, Salami M, Wojtowicz J, Lansdall CJ, Lane C, Kerchner GA, Smith J, Doody RS. Boess FG, et al. Among authors: scelsi ma. J Prev Alzheimers Dis. 2024;11(3):537-548. doi: 10.14283/jpad.2024.60. J Prev Alzheimers Dis. 2024. PMID: 38706270 Clinical Trial.
Validation of 3- and 5-point severity scales to assess ARIA-E.
Bracoud L, Klein G, Lyons M, Scelsi MA, Wojtowicz J, Bullain S, Purcell D, Fiebach JB, Barakos J, Suhy J. Bracoud L, et al. Among authors: scelsi ma. Alzheimers Dement (Amst). 2023 Nov 23;15(4):e12503. doi: 10.1002/dad2.12503. eCollection 2023 Oct-Dec. Alzheimers Dement (Amst). 2023. PMID: 38026755 Free PMC article.
Investigating associations between blood metabolites, later life brain imaging measures, and genetic risk for Alzheimer's disease.
Green RE, Lord J, Scelsi MA, Xu J, Wong A, Naomi-James S, Handy A, Gilchrist L, Williams DM, Parker TD, Lane CA, Malone IB, Cash DM, Sudre CH, Coath W, Thomas DL, Keuss S, Dobson R, Legido-Quigley C, Fox NC, Schott JM, Richards M, Proitsi P; Insight 46 study team. Green RE, et al. Among authors: scelsi ma. Alzheimers Res Ther. 2023 Feb 22;15(1):38. doi: 10.1186/s13195-023-01184-y. Alzheimers Res Ther. 2023. PMID: 36814324 Free PMC article.
Comparing ARIA-E severity scales and effects of treatment management thresholds.
Klein G, Scelsi MA, Barakos J, Fiebach JB, Bracoud L, Suhy J, Delmar P, Lyons M, Wojtowicz J, Bullain S, Barkhof F, Purcell D. Klein G, et al. Among authors: scelsi ma. Alzheimers Dement (Amst). 2022 Dec 2;14(1):e12376. doi: 10.1002/dad2.12376. eCollection 2022. Alzheimers Dement (Amst). 2022. PMID: 36474747 Free PMC article.
Trial of Prasinezumab in Early-Stage Parkinson's Disease.
Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, Postuma RB, Pavese N, Stocchi F, Azulay JP, Mollenhauer B, López-Manzanares L, Russell DS, Boyd JT, Nicholas AP, Luquin MR, Hauser RA, Gasser T, Poewe W, Ricci B, Boulay A, Vogt A, Boess FG, Dukart J, D'Urso G, Finch R, Zanigni S, Monnet A, Pross N, Hahn A, Svoboda H, Britschgi M, Lipsmeier F, Volkova-Volkmar E, Lindemann M, Dziadek S, Holiga Š, Rukina D, Kustermann T, Kerchner GA, Fontoura P, Umbricht D, Doody R, Nikolcheva T, Bonni A; PASADENA Investigators; Prasinezumab Study Group. Pagano G, et al. N Engl J Med. 2022 Aug 4;387(5):421-432. doi: 10.1056/NEJMoa2202867. N Engl J Med. 2022. PMID: 35921451 Clinical Trial.
20 results